# Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

> **NCT05830500** · PHASE4 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Medullary Thyroid Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride Capsule

## Key facts

- **NCT ID:** NCT05830500
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-19
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05830500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05830500, "Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05830500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*